Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000412415 | SCV000486690 | likely pathogenic | Junctional epidermolysis bullosa gravis of Herlitz | 2016-07-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001051370 | SCV001215521 | likely pathogenic | not provided | 2023-01-22 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 371173). This variant has not been reported in the literature in individuals affected with LAMC2-related conditions. This variant is present in population databases (rs771613805, gnomAD 0.004%). This sequence change affects an acceptor splice site in intron 1 of the LAMC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in LAMC2 are known to be pathogenic (PMID: 11907499, 16473856). |
Prevention |
RCV003897828 | SCV004715623 | likely pathogenic | LAMC2-related condition | 2024-01-18 | criteria provided, single submitter | clinical testing | The LAMC2 c.80-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. To our knowledge this variant has not been reported in the literature to date. This variant is reported in 0.0036% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Variants that disrupt the consensus splice acceptor site in LAMC2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |